Figure 1.
![Figure 1. Five-year survival probability on pooled meta-analysis. The analysis accounts for 7843 patients in whom CLL-IPI was applied at different points in the course of their disease (ie, at diagnosis [8 series] and time of first treatment [3 series]). SCAN, SCALE Scandinavian population-based case-control study.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/131/3/10.1182_blood-2017-09-806034/4/blood806034f1.jpeg?Expires=1735516348&Signature=k2pXftM9rbdvzsFyBLAMwCny7~TU2ng7i3Q3xU9iBEal0tR9XwuTSKbkhKOH~VZhs9sP7HB-bddaYdr4lQER6H52mx~e2~oQAu3V5XlPu6dXW5VTcbC2tg9JoH5uvtv~7LLEXdUmIo~PNEKgZxOQngyaG~ubTiD~TAG7Dm8r~NYO0gpWkLqtvyKfDqk097Vz7tq8Tr6gq3mdR4EzsZNUCdJuYZWotK-3pgneGmYOC1QGgSVA9ywWwu9A986nMqBBMsxBlXxUr5wl01AK-hLUBiX~AUIAg1SUpLdZ2BYURwSX36WcCbe-iejrOIaPABUpTgUhjM8kBDgVgSHYKXuXTQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Five-year survival probability on pooled meta-analysis. The analysis accounts for 7843 patients in whom CLL-IPI was applied at different points in the course of their disease (ie, at diagnosis [8 series] and time of first treatment [3 series]). SCAN, SCALE Scandinavian population-based case-control study.
